Forgot password?

Wechat
Email
Sign Up

Use Wechat scan code to follow the official account directly sign in

Sweep WeChat yards

Use Wechat scan code to follow the official account directly sign in

the Qr Code is useless
Refresh

Use Wechat scan code to follow the official account directly sign in

Waiting for the show Qr Code...
Forgot password?

Sign Up
Confirm

Agreement onAcademic agreement

Sign In

home > search >

Challenges and opportunities for development of an AIDS vaccine

Author:: Nabel, GJ
Journal:: NATURE
Issue Date:: 2001
Abstract(summary):: Among the devastating consequences of AIDS has been its epidemic spread in the developing world. The disease has caused unprecedented suffering, debilitation, loss of life anti disruption of family, social and economic stability. Because of the considerable expense and logistical difficulty in providing antiviral drugs to populations infected with the human immunodeficiency virus throughout the world, the biomedical community is looking towards vaccines to help solve this compelling problem.
Page:: 1002---1007

VIEW PDF

The preview is over

If you wish to continue, please create your membership or download this.

Create Membership

References

Kwong, PD, Wyatt, R, Majeed, S, Robinson, J, Sweet, RW, Sodroski, J, Hendrickson, WA. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates[J]. STRUCTURE,2000:1329---1339.
Wahlfors, JJ, Zullo, SA, Loimas, S, Nelson, DM, Morgan, RA. Evaluation of recombinant alphaviruses as vectors in gene therapy[J]. GENE THERAPY,2000:472---480.
Mascola, JR, Stiegler, G, VanCott, TC, Katinger, H, Carpenter, CB, Hanson, CE, Beary, H, Hayes, D, Frankel, SS, Birx, DL, Lewis, MG. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies[J]. NATURE MEDICINE,2000:207---210.
Monahan, PE, Samulski, RJ. AAV vectors: is clinical success on the horizon?[J]. GENE THERAPY,2000:24---30.
Trono, D. Lentiviral vectors: turning a deadly foe into a therapeutic agent[J]. GENE THERAPY,2000:20---23.
Davis, NL, Caley, IJ, Brown, KW, Betts, MR, Irlbeck, DM, McGrath, KM, Connell, MJ, Montefiori, DC, Frelinger, JA, Swanstrom, R, Johnson, PR, Johnston, RE. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles RID A-6892-2009[J]. JOURNAL OF VIROLOGY,2000:371---378.
Barouch, DH, Santra, S, Schmitz, JE, Kuroda, MJ, Fu, TM, Wagner, W, Bilska, M, Craiu, A, Zheng, XX, Krivulka, GR, Beaudry, K, Lifton, MA, Nickerson, CE, Trigona, WL, Punt, K, Freed, DC, Guan, LM, Dubey, S, Casimiro, D, Simon, A, Davies, ME, Chastain, M, Strom, TB, Gelman, RS, Montefiori, DC, Lewis, MG, Emini, EA, Shiver, JW, Letvin, NL. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination[J]. SCIENCE,2000:486---492.
Gardner, MJ, Doolan, DL, Hedstrom, RC, Wang, RB, Sedegah, M, Gramzinski, RA, Aguiar, JC, Wang, H, Margalith, M, Hobart, P, Hoffman, SL. DNA vaccines against malaria: Immunogenicity and protection in a rodent model[J]. JOURNAL OF PHARMACEUTICAL SCIENCES,1996:1294---1300.
JOHNSON, PR, COLLINS, PL. SEQUENCE COMPARISON OF THE PHOSPHOPROTEIN MESSENGER-RNAS OF ANTIGENIC SUBGROUP-A AND SUBGROUP-B OF HUMAN RESPIRATORY SYNCYTIAL VIRUS IDENTIFIES A HIGHLY DIVERGENT DOMAIN IN THE PREDICTED PROTEIN RID A-6892-2009[J]. JOURNAL OF GENERAL VIROLOGY,1990:481---485.
SAAG, MS, HAHN, BH, GIBBONS, J, LI, YX, PARKS, ES, PARKS, WP, SHAW, GM. EXTENSIVE VARIATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 INVIVO[J]. NATURE,1988:440---444.

Cited By

Sykes, KF, Lewis, MG, Squires, B, Johnston, SA. Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge[J]. VACCINE,2002:2382---2395.
Giomarelli, B, Provvedi, R, Meacci, F, Maggi, T, Medaglini, D, Pozzi, G, Mori, T, McMahon, JB, Gardella, R, Boyd, MR. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1[J]. AIDS,2002:1351---1356.
Piguet, V, Blauvelt, A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY,2002:365---369.
Smith, SM. HIV vaccine development in the nonhuman primate model of AIDS[J]. JOURNAL OF BIOMEDICAL SCIENCE,2002:100---111.
Bardhan, NR. Accounts from the field: A public relations perspective on global AIDS/HIV[J]. JOURNAL OF HEALTH COMMUNICATION,2002:221---244.
Sarkar, S, Kalia, V, Murphey-Corb, M, Montelaro, RC. Detailed analysis of CD4(+) Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope[J]. JOURNAL OF IMMUNOLOGY,2002:4001---4011.
Barouch, DH, Santra, S, Tenner-Racz, K, Racz, P, Kuroda, MJ, Schmitz, JE, Jackson, SS, Lifton, MA, Freed, DC, Perry, HC, Davies, ME, Shiver, JW, Letvin, NL. Potent CD4(+) T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF[J]. JOURNAL OF IMMUNOLOGY,2002:562---568.
Hudgens, MG. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials[J]. STATISTICS IN MEDICINE,2003:463---479.
Gilliam, BL, Redfield, RR. Therapeutic HIV vaccines[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY,2003:1536---1553.
Wang, LX. Bioorganic approaches towards HIV vaccine design[J]. CURRENT PHARMACEUTICAL DESIGN,2003:1771---1787.

Forgot password?

Forgot password?

Challenges and opportunities for development of an AIDS vaccine

VIEW PDF

Similar Literature

Submit Feedback

Payment method:Overseas users please pay with PayPal